The TGA has granted conditional approval to Iovance Biotherapeutics’ lifileucel, an autologous tumour-infiltrating lymphocyte therapy, bringing a new …
The TGA has granted conditional approval to Iovance Biotherapeutics’ lifileucel, an autologous tumour-infiltrating lymphocyte therapy, bringing a new …
AstraZeneca and Daiichi Sankyo’s antibody-drug conjugate wins two new indications based on pivotal DESTINY-Breast11 and DESTINY-Breast05 trials, reshaping …
BioMarin Pharmaceutical has announced positive pivotal Phase 3 results for VOXZOGO (vosoritide) in children with hypochondroplasia, the most …
The U.S. Food and Drug Administration has approved VEPPANU (vepdegestrant), marking a significant milestone as the first PROTAC …
The global Alzheimer’s disease drug development pipeline has reached an unprecedented scale in 2026, with 192 active clinical …
Global biopharmaceutical mergers and acquisitions have surged to $106 billion across 201 transactions in 2026, putting the sector …
Regulatory setback for one biotech contrasts with a major success in sleep disorder treatment, underscoring the high stakes …
Early results from a multi-centre trial indicate that BI-8721 may slow cognitive decline and reduce amyloid biomarkers in …
Major change in NIH policy mandates inclusion of organoids, computational models, or other non-animal methods in proposals, likely …
Adding atezolizumab to FOLFOX chemotherapy after surgery boosts disease-free survival in patients with surgically resected mismatch repair deficient …
Already a subscriber? Log in